QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PHVS

QT55Pharvaris N.V.
NASDAQ·Healthcare·Biotechnology·NL
Latest market price
32.80
-0.61-1.83%
OverviewShort InterestFilings
PHVSQT55Pharvaris N.V.·NASDAQ
OverviewShort InterestFilings
32.80-1.83%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own1.76%
Shs Outstand69.67M
Perf Week1.86%
Market Cap2.34BForward P/E-EPS next Y-2.70Insider Trans-0.07%Shs Float-Perf Month13.30%
Enterprise Value2.05BPEG3.95EPS next Q-0.85Inst Own-Short Float-Perf Quarter25.53%
Income-207624596.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y32.69%
Sales-P/B8.05EPS next Y10.41%ROA-65.13%Short Interest-Perf YTD18.20%
Book/sh3.92P/C-EPS next 5Y-ROE-67.40%52W High34.41 -4.68%Perf Year98.07%
Cash/sh4.09P/FCF-EPS past 3/5Y-ROIC-72.82%52W Low16.00 105.00%Perf 3Y-
Dividend Est.-EV/EBITDA-10.74Sales past 3/5Y-Gross Margin0.00%Volatility3.94% 3.12%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-20.38%Oper. Margin0.00%ATR (14)1.59Perf 10Y-
Dividend Ex-Date-Quick Ratio11.24Sales Y/Y TTM-Profit Margin0.00%RSI (14)59.92Recom2.14
Dividend Gr. 3/5Y-Current Ratio11.24EPS Q/Q17.65%SMA206.26%Beta0.82Target Price52.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA509.50%Rel Volume0.54Prev Close33.41
Employees108LT Debt/Eq0.00EarningsAug 11SMA20024.10%Avg Volume335.31KPrice32.80
IPO DateFeb 05, 2021Option/ShortYes / YesEPS/Sales Surpr.14.83% -Net Debt/EBITDA1.48Volume181,316Change-1.83%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedUBS$75 → $74
Apr-08-26InitiatedWolfe ResearchOutperform$42
Mar-09-26InitiatedRBC CapitalOutperform$52
Dec-04-25ReiteratedGuggenheimBuy$39
Dec-04-25ReiteratedMorgan StanleyOverweight$41
Dec-04-25ReiteratedOppenheimerOutperform$42 → $50
Dec-03-25ReiteratedLeerink Partners$28 → $38
Oct-15-25InitiatedH.CBuy$60
Oct-09-25UpgradeB of A SecuritiesUnderperform → Neutral
Oct-14-24ReiteratedOppenheimerOutperform$42
Latest News
Jun-15-26
Jun-15-2606:52AM
Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive UseBenzinga
Jun-12-26
Jun-12-2607:13PM
Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026 - SlideshowSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other515134
Research and Development14010771
Other Operating Expense100
Operating Income-192-158-105
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)403
Net Income Before Taxes-196-143-108
Income Taxes221
Consolidated Net Income-198-145-109
Net Income From Continuing Operations-198-145-109
Net Income-198-145-109
EPS (Recurring)-3.35-2.68-2.84
EPS (Basic, Before Extraordinaries)-3.35-2.68-2.84
EPS (Diluted)-3.35-2.68-2.84
EBITDA-195-158-108
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding595438
Market Capitalization1,637——
Operating Lease Expense
———
Insider Trading Volume
$34.64$30.66$26.68$22.70$18.72● Close Price0.00M1.12M2.25M3.37M4.49MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Modig BerndtChief Executive OfficerJun 15 '26Sale31.072,29171,173135,209Jun 17 12:00 AM
Nijdam AnnaPrincipal Accounting OfficerJun 04 '26Sale30.872,67082,42546,275Jun 08 12:00 AM
Nijdam AnnaPrincipal Accounting OfficerMay 22 '26Option Exercise20.0011,002220,04054,446May 26 12:00 AM
Nijdam AnnaPrincipal Accounting OfficerMay 22 '26Sale30.745,501169,08448,945May 26 12:00 AM
Monges VivianeDirectorMay 21 '26Sale30.299,667292,8535,500May 26 12:00 AM
Nassif David W.CFO / CLOMay 21 '26Sale30.3110,000303,076120,300May 26 12:00 AM
Nijdam AnnaPrincipal Accounting OfficerMay 21 '26Option Exercise20.003,65873,16050,774May 26 12:00 AM
Nijdam AnnaPrincipal Accounting OfficerMay 21 '26Sale30.601,82955,97148,945May 26 12:00 AM
Bjork ElisabethDirectorMay 20 '26Option Exercise8.0520,000161,00025,167May 22 12:00 AM
Bjork ElisabethDirectorMay 20 '26Sale29.3210,000293,16615,167May 22 12:00 AM
Modig BerndtChief Executive OfficerMay 18 '26Sale29.222,29266,977137,500May 20 12:00 AM
Abele Stefan AndreasChief Technical Ops OfficerMay 15 '26Sale29.828,748260,86435,194May 19 12:00 AM
Glassman RobertDirectorMay 15 '26Option Exercise22.3110,666237,95820,500May 19 12:00 AM
Glassman RobertDirectorMay 15 '26Sale29.8210,000298,24610,500May 19 12:00 AM
Souverijns WimChief Commercial OfficerMay 15 '26Sale29.9210,000299,16345,111May 19 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR